Pfizer reports that COVID-19 vaccine administration to children aged 5 to 11 years is adequately effective at one-third the dose in adults

Pfizer and BioNTech reported good results in Phase 2 and Phase 3 clinical trials of the COVID-19 vaccine in children aged 5 to 11 years. This report is the first in a major clinical trial of the COVID-19 vaccine in children under the age of 12.

Pfizer and BioNTech Announce Positive Topline Results From Pivotal Trial of COVID-19 Vaccine in Children 5 to 11 Years | Pfizer

Pfizer and BioNTech administered the COVID-19 vaccine twice at 21-day intervals to 2268 children aged 5 to 11 years. As a result, a strong immune response was observed one month after the second administration.

If you are 12 years old or older, you should administer 30 ㎍ of vaccine, but in clinical trials, the amount administered to the subjects was 10 ㎍.

Dr. Ugur Sahin, CEO and co-founder of BioNTec, said, 'We are pleased to be able to submit data on vaccination for school-age children before the winter season.' The safety profile and immunogenicity data for 11-year-old children are consistent with the data we obtained for other age groups vaccinated with high doses. '

Pfizer and BioNTech will publish the data from this Phase 3 trial as a scientifically peer-reviewed treatise.

The results for children under the age of 5 will be announced in 2021 at the earliest.